 |
|
The Effect of Excessive Anticoagulation on Mortality and Morbidity in Hospitalized Patients With Anticoagulant-Related Major Hemorrhage
Sophia Koo, BS;
Nils Kucher, MD;
Paul L. Nguyen, AB;
John Fanikos, RPh, MBA;
Peter W. Marks, MD, PhD;
Samuel Z. Goldhaber, MD
Arch Intern Med. 2004;164:1557-1560.
Background We aimed to determine the effect of excessive anticoagulation on morbidity and mortality in hospitalized patients with major anticoagulant-associated hemorrhage.
Methods We prospectively identified 101 consecutive inpatients admitted to Brigham and Women's Hospital with major bleeding occurring during administration of warfarin sodium, unfractionated heparin (UFH), or low-molecular-weight heparin (LMWH).
Results Fifty patients had excessive and 51 had nonexcessive anticoagulation. The overall mortality at 60 days was 26% (13/50) in the excessive group compared with 10% (5/51) in the nonexcessive group (P = .03). Excessive warfarin therapy was associated with an increased 60-day mortality (P = .049), in contrast to excessive anticoagulation with UFH or LMWH alone (P = .27) or UFH or LMWH as a "bridge" to warfarin therapy (P = .10). Multivariate regression identified excessive anticoagulation as an independent predictor of 60-day mortality (adjusted hazard ratio [HR], 4.17; 95% confidence interval [CI], 1.39-12.49; P = .01), along with intracranial hemorrhage (adjusted HR, 6.16; 95% CI, 1.75-21.67; P = .005) and active cancer (adjusted HR, 3.79; 95% CI, 1.13-12.70; P = .03). Excessive anticoagulation was also a significant predictor of the combined nonfatal end point of stroke, myocardial infarction, hypotension, critical anemia, and surgical or angiographic intervention at 30 days (HR, 2.17; 95% CI, 1.25-3.78; P = .006).
Conclusion In a cohort of patients with anticoagulation-associated hemorrhage, excessive anticoagulation contributed independently to increased morbidity and mortality.
From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. The authors have no relevant financial interest in this article.
RELATED LETTERS
Is Drug Monitoring a Main Cause of Excessive Anticoagulation?
Rachel Howard
Arch Intern Med. 2005;165(3):349.
EXTRACT
| FULL TEXT
A Correct Evaluation of Renal Function Could Decrease Bleeding Risk in Anticoagulated Elderly Patients
Enrique Antón
Arch Intern Med. 2005;165(3):349-350.
EXTRACT
| FULL TEXT
A Correct Evaluation of Renal Function Could Decrease Bleeding Risk in Anticoagulated Elderly Patients—Reply
Sophia Koo, Nils Kucher, John Fanikos, and Samuel Z. Goldhaber
Arch Intern Med. 2005;165(3):350.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Aortic Valve Replacement with a Mechanical Cardiac Valve Prosthesis
Emery et al.
Card Surg Adult 2008;3:841-856.
FULL TEXT
Use of newer anticoagulants in patients with chronic kidney disease
Lobo
Am J Health Syst Pharm 2007;64:2017-2026.
ABSTRACT
| FULL TEXT
Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin: Assessment of Incidence, Case-Fatality Rate, Time Course and Sites of Bleeding, and Risk Factors for Bleeding.
Douketis et al.
Arch Intern Med 2006;166:853-859.
ABSTRACT
| FULL TEXT
Is Drug Monitoring a Main Cause of Excessive Anticoagulation?
Howard
Arch Intern Med 2005;165:349-349.
FULL TEXT
A Correct Evaluation of Renal Function Could Decrease Bleeding Risk in Anticoagulated Elderly Patients--Reply
Koo et al.
Arch Intern Med 2005;165:350-350.
FULL TEXT
A Correct Evaluation of Renal Function Could Decrease Bleeding Risk in Anticoagulated Elderly Patients
Anton
Arch Intern Med 2005;165:349-350.
FULL TEXT
|
